Insulet is trading at $139.32, up 4.02%, as healthcare stocks rise amid a broader defensive rotation; no clear company-specific catalyst was identified. - Healthcare is up 2.12%. - Sector sentiment has been supported by strong Q3 results and raised guidance from UnitedHealth, alongside strong results from Johnson & Johnson. - The wider market is mixed, with the Nasdaq lower and the Dow higher, so broad-market direction alone does not explain the move.